Evidence map›Paper›PMID 34442416›Full record

ArticleJournal of personalized medicine2021

Genetic Variants in PGE2 Receptors Modulate the Risk of Nephrosclerosis and Clinical Outcomes in These Patients.

Luz María González, Nicolás Roberto Robles, Sonia Mota-Zamorano, José Manuel Valdivielso, Juan López-Gómez, Guillermo Gervasini

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of personalized medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. The Link between Prostanoids and Cardiovascular Diseases.International journal of molecular sciences · 2023
    Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Luz María GonzálezDepartment of Medical and Surgical Therapeutics, Division of Pharmacology, Medical School, University of Extremadura, 06006 Badajoz, Spain.
Nicolás Roberto RoblesService of Nephrology, Badajoz University Hospital, 06080 Badajoz, Spain.
Sonia Mota-ZamoranoDepartment of Medical and Surgical Therapeutics, Division of Pharmacology, Medical School, University of Extremadura, 06006 Badajoz, Spain.
José Manuel ValdivielsoVascular and Renal Translational Research Group, UDETMA, ISCIII REDinREN, IRBLleida, 25198 Lleida, Spain.ORCID 0000-0003-1343-0184
Juan López-GómezService of Clinical Analyses, Badajoz University Hospital, 06080 Badajoz, Spain.
Guillermo GervasiniDepartment of Medical and Surgical Therapeutics, Division of Pharmacology, Medical School, University of Extremadura, 06006 Badajoz, Spain.
Universidad de Extremadura · ESCentro de Implantología Cirugía Oral y Maxilofacial · ESInstituto de Salud Carlos III · ES

Funding

Instituto de Salud Carlos III PI18/00745Junta de Extremadura IB16014 ; GR18007
6 · The paper itself

Abstract

Prostaglandin E2 (PGE2) is a major actor mediating renal injury. We aimed to determine genetic variability in the genes coding for its receptors (

Indexed as

cardiovascular riskEP receptorsnephrosclerosisPGE2

Identifiers

PMID34442416
PMCPMC8400263
OpenAlexW3191104855

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.